Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBT: 2021-2024

Historic EBT for Immunocore Holdings (IMCR) over the last 4 years, with Dec 2024 value amounting to -$52.9 million.

  • Immunocore Holdings' EBT fell 95.01% to $304,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.1 million, marking a year-over-year increase of 47.68%. This contributed to the annual value of -$52.9 million for FY2024, which is 13.06% up from last year.
  • Latest data reveals that Immunocore Holdings reported EBT of -$52.9 million as of FY2024, which was up 13.06% from -$60.9 million recorded in FY2023.
  • In the past 5 years, Immunocore Holdings' EBT ranged from a high of -$40.9 million in FY2022 and a low of -$179.9 million during FY2021.
  • Over the past 3 years, Immunocore Holdings' median EBT value was -$52.9 million (recorded in 2024), while the average stood at -$51.6 million.
  • In the last 5 years, Immunocore Holdings' EBT spiked by 77.27% in 2022 and then plummeted by 48.94% in 2023.
  • Over the past 4 years, Immunocore Holdings' EBT (Yearly) stood at -$179.9 million in 2021, then soared by 77.27% to -$40.9 million in 2022, then tumbled by 48.94% to -$60.9 million in 2023, then rose by 13.06% to -$52.9 million in 2024.